Brand-Ad-30-6
 IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4284 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE here  
     Search
     Current Issue
     Submit Article 
     My Preferences 
     Dermatology crossword 

 


This article has been cited by
1Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Min Li,Ying Zhou,Chaoyang Chen,Ting Yang,Shuang Zhou,Shuqing Chen,Ye Wu,Yimin Cui
Orphanet Journal of Rare Diseases.2019;14(1)
[DOI]
2Neue Entwicklungen bei Topika
Johannes Wohlrab
Der Hautarzt.2019;70(12)953
[DOI]
3The use of rapamycin in patients with tuberous sclerosis complex: Long-term results
Mehmet Canpolat,Hakan Gumus,Sefer Kumandas,Abdulhakim Coskun,Huseyin Per
Epilepsy & Behavior.2018;88(12)357
[DOI]
4The use of rapamycin in patients with tuberous sclerosis complex: Long-term results
Marley L. Watson,Bridgette K. Schroader,Heather D. Nelkin
Epilepsy & Behavior.2018;40(12)489
[DOI]
5Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis
Sophie Leducq,Bruno Giraudeau,Elsa Tavernier,Annabel Maruani
Journal of the American Academy of Dermatology.2019;80(3)735
[DOI]
Online since 15th March '04
Published by Wolters Kluwer - Medknow